BioLineRx to Report Third Quarter 2021 Results on November 18, 2021
BioLineRx Ltd. (NASDAQ: BLRX) plans to release its unaudited financial results for Q3 2021 on November 18, 2021, before U.S. markets open. A conference call will follow at 10:00 a.m. EST, featuring CEO Philip Serlin. Investors can access the call via the Investor Relations page. The lead oncology program, Motixafortide (BL-8040), is preparing for NDA submission after positive trial results. A second program, AGI-134, is in Phase 1/2a studies.
- None.
- None.
TEL AVIV, Israel, Nov. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2021 on Thursday, November 18, 2021, before the US markets open.
The Company will host a conference call on Thursday, November 18, 2021 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
To dial into the conference call, please dial +1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until November 21, 2021; please dial +1-888-295-2634 from the U.S. or +972-3-925-5904 internationally.
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.
The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has reported positive results from a pre-planned pharmacoeconomic study, and is currently in preparations for an NDA submission. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a clinical trial collaboration agreement with MSD (BioLineRx owns all rights to Motixafortide), and is currently being studied in combination with LIBTAYO® and chemotherapy as a first-line PDAC therapy.
BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.
For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events.
Contact:
Tim McCarthy
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com
or
Moran Meir
LifeSci Advisors, LLC
+972-54-476-4945
moran@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2021-results-on-november-18-2021-301422992.html
SOURCE BioLineRx Ltd.
FAQ
When will BioLineRx report its financial results for Q3 2021?
What time is the BioLineRx conference call on November 18, 2021?
How can I access the BioLineRx conference call?
What is the lead oncology program of BioLineRx?
What trials has Motixafortide undergone?
What is AGI-134 in relation to BioLineRx?
